Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MURTAZA ADAM

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1093004806
CMS profile
1388640
Location
PARKER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$170,812.33

145 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MURTAZA ADAM

NPI 1093004806 · CMS profile ID 1388640

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

PARKER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093004806?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MURTAZA ADAM, NPI 1093004806, CMS profile ID 1388640. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093004806?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MURTAZA ADAM, NPI 1093004806, CMS profile ID 1388640. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093004806?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MURTAZA ADAM, NPI 1093004806, CMS profile ID 1388640, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–145 of 145 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1093004806?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

145 matching records · $170,812.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 145 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–145 of 145.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $8,464.0004/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994307 CMS
Regeneron Healthcare Solutions, Inc. $164.2504/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994305 CMS
Regeneron Healthcare Solutions, Inc. $121.8004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994303 CMS
Apellis Pharmaceuticals, Inc. $33.9004/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154026798 CMS
Regeneron Healthcare Solutions, Inc. $2,116.0004/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994301 CMS
Genentech USA, Inc. $5.8004/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133076909 CMS
Astellas Pharma US Inc $9,350.0004/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450192 CMS
Astellas Pharma US Inc $34.3104/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453768 CMS
Astellas Pharma US Inc $59.6304/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453770 CMS
Astellas Pharma US Inc $66.5104/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453772 CMS
Astellas Pharma US Inc $74.3104/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453774 CMS
Astellas Pharma US Inc $60.1104/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453804 CMS
Apellis Pharmaceuticals, Inc. $1,500.0004/09/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154026810 CMS
Astellas Pharma US Inc $325.3304/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450082 CMS
Astellas Pharma US Inc $146.4504/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450084 CMS
Astellas Pharma US Inc $223.1904/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453798 CMS
Astellas Pharma US Inc $550.0003/20/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450422 CMS
ABBVIE INC. $18.8703/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103173034 CMS
ABBVIE INC. $10.7303/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103173032 CMS
Regeneron Healthcare Solutions, Inc. $239.9103/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994299 CMS
Astellas Pharma US Inc $6,050.0003/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450534 CMS
Astellas Pharma US Inc $92.5803/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453606 CMS
Hoffmann-La Roche Limited $6,300.0002/29/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133076990 CMS
Astellas Pharma US Inc $550.0002/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453490 CMS
Astellas Pharma US Inc $97.4102/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450460 CMS
Astellas Pharma US Inc $11.8202/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450478 CMS
Astellas Pharma US Inc $9,350.0002/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450480 CMS
Astellas Pharma US Inc $80.2202/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453612 CMS
Astellas Pharma US Inc $44.5802/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453614 CMS
Astellas Pharma US Inc $84.5002/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453658 CMS
Astellas Pharma US Inc $61.0902/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453660 CMS
ABBVIE INC. $18.9402/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103173030 CMS
Astellas Pharma US Inc $137.4902/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450482 CMS
Astellas Pharma US Inc $239.3802/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139450484 CMS
Astellas Pharma US Inc $352.1902/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139453616 CMS
Apellis Pharmaceuticals, Inc. $180.0002/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154026800 CMS
Apellis Pharmaceuticals, Inc. $180.0002/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154026814 CMS
Regeneron Healthcare Solutions, Inc. $529.0001/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994297 CMS
Genentech USA, Inc. $20.8001/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133076905 CMS
Apellis Pharmaceuticals, Inc. $1,500.0001/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154026816 CMS
Regeneron Healthcare Solutions, Inc. $150.6001/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994295 CMS
Regeneron Healthcare Solutions, Inc. $29.4801/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994293 CMS
Regeneron Healthcare Solutions, Inc. $99.7001/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994289 CMS
Regeneron Healthcare Solutions, Inc. $53.7501/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994291 CMS
Regeneron Healthcare Solutions, Inc. $8,464.0001/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113994287 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,825.34 58
PY2020 $15,845.60 20
PY2021 $32,457.04 41
PY2022 $32,132.36 39
PY2023 $138,444.19 119
PY2024 $170,812.33 145
PY2025 $124,791.22 79

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $229,400.29 341
PY2024 Recipient $7,361.07 3
PY2024 Principal investigator $230,631.74 52
PY2023 Principal investigator $220,166.00 23
PY2022 Principal investigator $107,547.11 15
PY2021 Principal investigator $216,766.77 41
PY2020 Principal investigator $326,216.52 17
PY2019 Principal investigator $176,747.20 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

341 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,526.20 12/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184279994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277916
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,370.95 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,829.95 12/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184277930
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274873
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274893
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274901
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274911
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274913
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.00 12/12/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184274931
Principal investigator 1 ABBVIE INC. $162.00 12/11/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202530120
Principal investigator 1 ABBVIE INC. $226.80 12/11/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202530130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $459.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269827
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269829
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269839
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269843
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 12/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184269851
Principal investigator 1 ABBVIE INC. $11,162.00 12/04/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) No dispute reported 06/30/2026 1202528008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 12/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184267783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $64.50 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $64.50 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $918.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $202.50 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266967
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $310.00 12/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266969
Principal investigator 1 ABBVIE INC. $6,120.00 11/26/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) No dispute reported 06/30/2026 1202525606
Principal investigator 1 ABBVIE INC. $226.80 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202524704
Principal investigator 1 ABBVIE INC. $33.75 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202524708
Principal investigator 1 ABBVIE INC. $33.75 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202524710
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,358.45 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,829.95 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/19/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 11/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $405.00 11/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $540.00 11/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184261703
Principal investigator 1 Genentech, Inc. $48.60 11/13/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211590043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $43.23 11/05/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184257483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 10/29/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 10/29/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $371.00 10/29/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 10/29/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 10/29/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 10/29/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184253999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 10/29/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184254001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/29/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184254003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $155.00 10/29/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184254005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 10/23/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184252900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 10/23/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184252902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 10/23/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184252904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,370.95 10/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,526.20 10/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,638.60 10/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 10/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 10/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251163
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,370.95 10/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 10/17/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184244987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184244989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184244991
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184244993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184244995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184244997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184244999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184245001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184245005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184245007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184245009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184245013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184245015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184245017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 10/03/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184245019
Principal investigator 1 ABBVIE INC. $6,755.40 10/01/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202512992
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184237528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 09/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184237530
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184237532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 09/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184237534
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184237536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 09/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184237538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 09/11/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184236067
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 09/11/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184236069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235743
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235745
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235747
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235755
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 09/10/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184235793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184230759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184230761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184230763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184230765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184230767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184230927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184230929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184230933
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231141
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231157
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231173
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28.05 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184231753
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,358.45 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232260
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,370.95 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232262
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232274
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232286
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232566
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,638.60 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232896
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232898
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232900
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232906
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232928
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232942
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232944
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232946
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184232960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 08/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184233142
Principal investigator 1 ABBVIE INC. $3,207.60 08/27/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184222506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 07/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184222508
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 07/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184222512
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184222514
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184222516
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184222520
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184222522
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 07/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184222524
Principal investigator 1 ABBVIE INC. $195.75 07/25/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202499846
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218395
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218413
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218423
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218439
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $203.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 07/24/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184218453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,358.45 07/14/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 07/14/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 07/14/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214924
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $129.00 07/11/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184214818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,526.20 07/09/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 07/09/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,638.60 07/09/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,414.80 07/09/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184213411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101.00 06/30/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184212319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,358.45 06/27/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,526.20 06/27/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 06/27/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,638.60 06/27/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184211961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 06/18/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 06/18/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 06/18/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184207923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 06/18/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 06/18/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208087
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 06/18/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 06/18/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,300.00 06/18/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 06/18/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184208937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $93.16 05/28/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184200085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,638.60 05/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184196069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,531.60 05/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184196071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,526.20 05/15/2025 Non-covered Recipient Entity
COLORADO RETINA ASSOCIATES PC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184196075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,500.00 02/05/2025 Non-covered Recipient Entity
COLORADORETINAASSOCIATESPC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184152099